Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MATTHEW ALEXANDER CUNNINGHAM

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1336303247
CMS profile
150859
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$78,505.14

72 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Genentech USA, Inc. $18,891.83 5
Apellis Pharmaceuticals, Inc. $18,042.63 13
Regeneron Healthcare Solutions, Inc. $17,702.15 13
Astellas Pharma US Inc $13,922.28 13
Alcon Vision LLC $3,156.57 8
Ocular Therapeutix, Inc. $2,438.32 3
ANI Pharmaceuticals, Inc. $2,273.77 9
Alcon Research LLC $1,860.00 1
ABBVIE INC. $193.46 6
Neurotech Pharmaceuticals, Inc. $24.13 1

Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MATTHEW ALEXANDER CUNNINGHAM

NPI 1336303247 · CMS profile ID 150859

Allopathic & Osteopathic Physicians / Ophthalmology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336303247?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MATTHEW ALEXANDER CUNNINGHAM, NPI 1336303247, CMS profile ID 150859. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336303247?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MATTHEW ALEXANDER CUNNINGHAM, NPI 1336303247, CMS profile ID 150859. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336303247?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MATTHEW ALEXANDER CUNNINGHAM, NPI 1336303247, CMS profile ID 150859, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1336303247?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

72 matching records · $78,505.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 72 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–72 of 72.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $1,000.0005/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238708480 CMS
ANI Pharmaceuticals, Inc. $135.0805/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248595668 CMS
Regeneron Healthcare Solutions, Inc. $27.6605/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212897389 CMS
Ocular Therapeutix, Inc. $38.3205/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250232361 CMS
Regeneron Healthcare Solutions, Inc. $129.4605/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212897387 CMS
Astellas Pharma US Inc $33.9804/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238777154 CMS
Astellas Pharma US Inc $6,000.0004/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238632003 CMS
Astellas Pharma US Inc $1,101.4104/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238632237 CMS
Astellas Pharma US Inc $133.0004/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238632373 CMS
Ocular Therapeutix, Inc. $800.0003/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250232353 CMS
Apellis Pharmaceuticals, Inc. $1,500.0003/25/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1253200464 CMS
Astellas Pharma US Inc $37.8103/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238762542 CMS
ANI Pharmaceuticals, Inc. $11.8603/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248631364 CMS
Genentech USA, Inc. $26.9503/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211546233 CMS
ABBVIE INC. $3.7303/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201713227 CMS
Regeneron Healthcare Solutions, Inc. $994.8603/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212897383 CMS
Regeneron Healthcare Solutions, Inc. $5,640.0003/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212897385 CMS
Regeneron Healthcare Solutions, Inc. $113.8502/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212897381 CMS
Regeneron Healthcare Solutions, Inc. $26.3102/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212897379 CMS
ABBVIE INC. $90.2002/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201713225 CMS
ABBVIE INC. $21.4101/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201713223 CMS
Alcon Vision LLC $1,000.0001/23/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1224271164 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21,829.45 40
PY2020 $3,271.78 20
PY2021 $6,983.33 43
PY2022 $42,470.66 53
PY2023 $146,526.66 114
PY2024 $100,814.40 93
PY2025 $78,505.14 72

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $8,282.45 4
PY2025 Principal investigator $932,857.15 327
PY2024 Recipient $21,476.61 17
PY2024 Principal investigator $915,142.20 265
PY2023 Recipient $2,205.25 2
PY2023 Principal investigator $208,426.12 33
PY2022 Recipient $1,320.00 1
PY2022 Principal investigator $199,502.53 12
PY2021 Principal investigator $150,309.24 30
PY2020 Principal investigator $74,243.00 16
PY2019 Principal investigator $45,336.55 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

331 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279656
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279658
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 12/18/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277290
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/18/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277292
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 12/18/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277294
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270579
Principal investigator 1 Genentech, Inc. $13.96 12/10/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211606529
Principal investigator 1 Genentech, Inc. $3,173.68 12/09/2025 Non-covered Recipient Entity
Florida Retina Institute
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211606370
Principal investigator 1 Genentech, Inc. $5,500.00 12/05/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211606515
Principal investigator 1 Genentech, Inc. $7,086.00 12/05/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211606520
Principal investigator 1 Genentech, Inc. $6,103.53 12/05/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211606534
Principal investigator 1 ABBVIE INC. $11,162.00 12/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) No dispute reported 06/30/2026 1202528820
Principal investigator 1 Genentech, Inc. $13.96 12/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211606538
Principal investigator 1 Genentech, Inc. $532.00 12/01/2025 Non-covered Recipient Entity
Florida Retina Institute
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211606374
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 12/01/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/01/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $142.00 12/01/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $82.00 12/01/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 12/01/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/01/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $149.00 12/01/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $109.34 11/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265591
Principal investigator 1 ABBVIE INC. $6,120.00 11/26/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) No dispute reported 06/30/2026 1202525666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/24/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184263969
Principal investigator 1 Genentech, Inc. $35,920.00 11/20/2025 Non-covered Recipient Entity
Retina Group d/b/a Retina Consultants of America
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211645733
Principal investigator 1 Genentech, Inc. $26,430.00 11/19/2025 Non-covered Recipient Entity
Florida Retina Institute
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211606368
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/17/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/17/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/17/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 11/17/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 11/17/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $314.00 11/17/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261553
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 11/12/2025 Non-covered Recipient Entity
RETINA VITREOUS CONSULTANTS LLPRETINA GROUP OF FLORIDA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238533
Principal investigator 1 Ocular Therapeutix, Inc. $142,530.00 11/12/2025 Non-covered Recipient Entity
RETINA VITREOUS CONSULTANTS LLPRETINA GROUP OF FLORIDA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238535
Principal investigator 1 Genentech, Inc. $9,520.00 11/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211606510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/29/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253276
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253278
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253282
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253284
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253286
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253288
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253290
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253292
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253294
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253298
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253300
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253302
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253306
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253308
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253310
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253312
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/27/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253314
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184252916
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184252918
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184252920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184252922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 10/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184252924
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 10/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184252926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,638.60 10/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184252928
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/22/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251648
Principal investigator 1 Genentech, Inc. $6,000.00 10/16/2025 Non-covered Recipient Entity
Florida Retina Institute
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211606360
Principal investigator 1 Genentech, Inc. $1,230.00 10/16/2025 Non-covered Recipient Entity
Florida Retina Institute
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211606364
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/13/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249869
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/09/2025 Non-covered Recipient Entity
RETINA VITREOUS CONSULTANTS LLPRETINA GROUP OF FLORIDA
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.92 10/08/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $88.20 10/08/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.82 10/08/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/25/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242541
Principal investigator 1 Genentech, Inc. $12.68 09/24/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211606493
Principal investigator 1 Genentech, Inc. $2,818.00 09/24/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211606497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,639.35 09/24/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184235941
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $680.00 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410388
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $150.00 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410476
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $121.18 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410590
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $276.91 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410642
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,012.50 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410686
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $87.75 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410692
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410758
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,500.00 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410864
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,000.00 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410904
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,077.60 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410906
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $875.00 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410910
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $250.00 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410912
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,344.14 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410974
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,976.75 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410990
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $87.75 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411036
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $228.33 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411144
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411194
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $21,600.00 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411318
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,813.69 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411396
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,500.00 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411414
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,181.25 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411418
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $87.75 09/08/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411424
Recipient F. Hoffmann-La Roche AG $565.91 08/29/2025 Covered Recipient Physician Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US No dispute reported 06/30/2026 1211537583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/28/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184232244
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/28/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184232246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/28/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184232248
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/14/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184227943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/14/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184227945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 08/14/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184227947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 08/14/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184227949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/14/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184227951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/14/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184227953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 08/14/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184227955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 08/14/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184227957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.75 08/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184225961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 08/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184225963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224544
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224552
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224554
Principal investigator 1 Genentech, Inc. $14,692.00 08/01/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211606505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $474.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,205.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222210
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222212
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222214
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222216
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/25/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/25/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/25/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/25/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/25/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/25/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/25/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184218563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215050
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215062
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215064
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215066
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215068
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 07/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184214664
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184214666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.00 07/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184214668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 07/11/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184214670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $474.00 07/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.00 07/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 07/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 07/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 07/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.00 07/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.00 07/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,300.00 07/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209484
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209486
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209488
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209490
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209492
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209498
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.75 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209504
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.75 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209506
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.75 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.75 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.75 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.75 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209514
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.75 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.75 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.75 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.75 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.75 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209524
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.78 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $390.88 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209716
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209718
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $654.74 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $654.74 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $654.74 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,638.68 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,638.68 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209850
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,838.00 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184209910
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $59.40 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184210016
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $59.40 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184210018
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $59.40 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184210020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.25 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184210036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.25 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184210040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.25 06/20/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184210042
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184203833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,000.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184203861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184203999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184204001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184204003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184204005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184204007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/26/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/26/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198739
Principal investigator 1 ANI Pharmaceuticals, Inc. $15,279.49 05/15/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
New Day Study No dispute reported 06/30/2026 1248567661
Principal investigator 1 ANI Pharmaceuticals, Inc. $15,279.49 05/15/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
New Day Study No dispute reported 06/30/2026 1248567675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184193673
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 04/28/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406608
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,850.15 04/28/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225407086
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,850.15 04/28/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225407126
Principal investigator 1 ANI Pharmaceuticals, Inc. $1,485.00 04/24/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
New Day Study No dispute reported 06/30/2026 1248567615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 04/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184183516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184183518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 04/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184183520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184183522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 04/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184183524
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184183526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184183528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184183530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 04/16/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184183532
Recipient F. Hoffmann-La Roche AG $607.27 03/31/2025 Covered Recipient Physician Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US No dispute reported 06/30/2026 1211537587
Recipient F. Hoffmann-La Roche AG $607.27 03/31/2025 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211537591
Recipient F. Hoffmann-La Roche AG $6,502.00 03/31/2025 Covered Recipient Physician Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US No dispute reported 06/30/2026 1211537595
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 03/24/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225403823
Principal investigator 1 Genentech, Inc. $23,023.00 03/21/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211606490
Principal investigator 1 ANI Pharmaceuticals, Inc. $85,814.19 03/19/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
New Day Study No dispute reported 06/30/2026 1248567671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173236
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173238
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173240
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173242
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173244
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173248
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,850.15 02/28/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406466
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 02/27/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225402763
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 02/27/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225403183
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 02/27/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404189
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 02/27/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405814
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 02/27/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406610
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 02/27/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225407128
Principal investigator 1 ANI Pharmaceuticals, Inc. $1,950.30 02/24/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
New Day Study No dispute reported 06/30/2026 1248567581
Principal investigator 1 ANI Pharmaceuticals, Inc. $2,100.00 02/21/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
New Day Study No dispute reported 06/30/2026 1248567491
Principal investigator 1 ANI Pharmaceuticals, Inc. $750.00 02/17/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
New Day Study No dispute reported 06/30/2026 1248567417
Principal investigator 1 Genentech, Inc. $1,592.00 02/07/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211606485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,500.00 02/05/2025 Non-covered Recipient Entity
FLORIDA RETINA INSTITUTE
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184152266
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,684.10 01/30/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225402761
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,850.15 01/30/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225403567
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,850.15 01/30/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405106
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,850.15 01/30/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405108
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 01/30/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405746
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 01/30/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405748
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 01/30/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406440
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,850.15 01/30/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406442
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.70 01/30/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225407082
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,850.15 01/30/2025 Non-covered Recipient Entity
Florida Retina Institute Orlando
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225407084

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2023 Amount invested $0.00 1
PY2023 Value of interest $3,187.10 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $2,500.00 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $2,500.00 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $2,777.78 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $2,777.78 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

5 records · PY2019–2023

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2023 US Retina LLC $0.00 $3,187.10 Membership Interest Physician Covered Recipient No dispute reported 06/30/2026 1052376703
PY2022 US Retina LLC $0.00 $2,500.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 951869602
PY2021 US Retina LLC $0.00 $2,500.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 856668973
PY2020 US Retina LLC $0.00 $2,777.78 Shares Physician Covered Recipient No dispute reported 06/30/2026 714311267
PY2019 US Retina LLC $0.00 $2,777.78 Shares Physician Covered Recipient No dispute reported 06/30/2026 655842699